174 related articles for article (PubMed ID: 35723296)
1. Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line.
Aldén M; Olofsson Falla F; Yang D; Barghouth M; Luan C; Rasmussen M; De Marinis Y
Curr Issues Mol Biol; 2022 Feb; 44(3):1115-1126. PubMed ID: 35723296
[TBL] [Abstract][Full Text] [Related]
2. Comment on Aldén et al. Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line.
Merchant HA
Curr Issues Mol Biol; 2022 Apr; 44(4):1661-1663. PubMed ID: 35723371
[TBL] [Abstract][Full Text] [Related]
3. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
[TBL] [Abstract][Full Text] [Related]
4. Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12-17 Years - Arizona, July-December 2021.
Lutrick K; Rivers P; Yoo YM; Grant L; Hollister J; Jovel K; Khan S; Lowe A; Baccam Z; Hanson H; Olsho LEW; Fowlkes A; Caban-Martinez AJ; Porter C; Yoon S; Meece J; Gaglani M; Burns J; Mayo Lamberte J; Nakayima Miiro F; Bissonnette A; LeClair L; Kutty PK; Romine JK; Stefanski E; Edwards LJ; Ellingson K; Gerald JK; Bedrick EJ; Madhivanan P; Krupp K; Gerald LB; Thompson M; Burgess JL
MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(5152):1761-1765. PubMed ID: 34968373
[TBL] [Abstract][Full Text] [Related]
5. Side Effects of COVID-19 Pfizer-BioNTech mRNA Vaccine in Children Aged 12-18 Years in Saudi Arabia.
Alamer E; Alhazmi A; Qasir NA; Alamer R; Areeshi H; Gohal G; Qadri M; Hashem AM; Algaissi A
Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835228
[No Abstract] [Full Text] [Related]
6. Comparison of Moderna versus Pfizer-BioNTech COVID-19 vaccine outcomes: A target trial emulation study in the U.S. Veterans Affairs healthcare system.
Ioannou GN; Locke ER; Green PK; Berry K
EClinicalMedicine; 2022 Mar; 45():101326. PubMed ID: 35261970
[TBL] [Abstract][Full Text] [Related]
7. Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States.
Di Fusco M; Marczell K; Deger KA; Moran MM; Wiemken TL; Cane A; de Boisvilliers S; Yang J; Vaghela S; Roiz J
J Med Econ; 2022; 25(1):605-617. PubMed ID: 35574613
[TBL] [Abstract][Full Text] [Related]
8. Demographic and Clinical Factors Associated With Anti-SARS-CoV-2 Antibody Levels After 2 BNT162b2 mRNA Vaccine Doses.
Nam SY; Jeon SW; Lee HS; Lim HJ; Lee DW; Yoo SS
JAMA Netw Open; 2022 May; 5(5):e2212996. PubMed ID: 35587345
[TBL] [Abstract][Full Text] [Related]
9. Tozinameran (BNT162b2) Vaccine: The Journey from Preclinical Research to Clinical Trials and Authorization.
Khehra N; Padda I; Jaferi U; Atwal H; Narain S; Parmar MS
AAPS PharmSciTech; 2021 Jun; 22(5):172. PubMed ID: 34100150
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
11. Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany.
Gomes D; Beyerlein A; Katz K; Hoelscher G; Nennstiel U; Liebl B; Überla K; von Kries R
PLoS One; 2021; 16(11):e0259370. PubMed ID: 34739520
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
[TBL] [Abstract][Full Text] [Related]
13. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients.
Rabinowich L; Grupper A; Baruch R; Ben-Yehoyada M; Halperin T; Turner D; Katchman E; Levi S; Houri I; Lubezky N; Shibolet O; Katchman H
J Hepatol; 2021 Aug; 75(2):435-438. PubMed ID: 33892006
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk.
Shavit R; Maoz-Segal R; Iancovici-Kidon M; Offengenden I; Haj Yahia S; Machnes Maayan D; Lifshitz-Tunitsky Y; Niznik S; Frizinsky S; Deutch M; Elbaz E; Genaim H; Rahav G; Levy I; Belkin A; Regev-Yochay G; Afek A; Agmon-Levin N
JAMA Netw Open; 2021 Aug; 4(8):e2122255. PubMed ID: 34463744
[TBL] [Abstract][Full Text] [Related]
15. Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) Side Effects: A Systematic Review.
Dighriri IM; Alhusayni KM; Mobarki AY; Aljerary IS; Alqurashi KA; Aljuaid FA; Alamri KA; Mutwalli AA; Maashi NA; Aljohani AM; Alqarni AM; Alfaqih AE; Moazam SM; Almutairi MN; Almutairi AN
Cureus; 2022 Mar; 14(3):e23526. PubMed ID: 35494952
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of mRNA BNT162b2 COVID-19 vaccine against SARS-CoV-2 Delta variant among elderly residents from a long-term care facility, South of France, May 2021.
Sánchez Ruiz MA; Adonias G; Robaglia-Schlupp A; Rapilly F; Chabert M; Ramalli L; Reilhes O; Bruel C; Malfait P; Chaud P
Eur Rev Med Pharmacol Sci; 2022 Apr; 26(7):2586-2591. PubMed ID: 35442474
[TBL] [Abstract][Full Text] [Related]
17. The effectiveness of BNT162b2 mRNA vaccine against COVID-19 caused by Delta variant of SARS-CoV-2: a systematic review and meta-analysis.
Kow CSC; Ramachandram DS; Hasan SS
Inflammopharmacology; 2022 Feb; 30(1):149-157. PubMed ID: 35099680
[TBL] [Abstract][Full Text] [Related]
18. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients.
Havlin J; Svorcova M; Dvorackova E; Lastovicka J; Lischke R; Kalina T; Hubacek P
J Heart Lung Transplant; 2021 Aug; 40(8):754-758. PubMed ID: 34120839
[TBL] [Abstract][Full Text] [Related]
20. Persistence of Immune Response in Health Care Workers After Two Doses BNT162b2 in a Longitudinal Observational Study.
Herzberg J; Fischer B; Lindenkamp C; Becher H; Becker AK; Honarpisheh H; Guraya SY; Strate T; Knabbe C
Front Immunol; 2022; 13():839922. PubMed ID: 35309303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
